Showing results (931-940 of 988) with videos related to
Sort By:
Pageof 99
Bioorganic & Medicinal Chemistry Letters|January 25, 2011
Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthaleneJonathan Y Bass, Justin A Caravella, Lihong Chen, et al.Journal of Medicinal Chemistry|December 7, 2010
Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonistsDaniel J Parks, William H Parsons, Raymond W Colburn, et al.Nature Medicine|February 23, 2010
Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeysSampa Santra, Hua-Xin Liao, Ruijin Zhang, et al.Journal of Virology|February 4, 2012
Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine designMattia Bonsignori, David C Montefiori, Xueling Wu, et al.The Lancet. Haematology|March 10, 2022
Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trialNicholas Crombie, Heidi A Doughty, Jonathan R B Bishop, et al.Journal of Medicinal Chemistry|May 3, 2002
Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary aminesJon L Collins, Adam M Fivush, Michael A Watson, et al.Bioorganic & Medicinal Chemistry Letters|July 10, 2009
FXR agonist activity of conformationally constrained analogs of GW 4064Adwoa Akwabi-Ameyaw, Jonathan Y Bass, Richard D Caldwell, et al.Autism Research : Official Journal of the International Society for Autism Research|January 22, 2020
Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene DeletionAndie Dodge, Melinda M Peters, Hayden E Greene, et al.Plos One|December 4, 2008
The evolution of invasiveness in garden antsSylvia Cremer, Line V Ugelvig, Falko P Drijfhout, et al.Journal of Medicinal Chemistry|December 4, 1998
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituentJ E Cobb, S G Blanchard, E G Boswell, et al.Pageof 99